HRP20140194T1 - Nova sol metformin glicinat za kontrolu glukoze u krvi - Google Patents
Nova sol metformin glicinat za kontrolu glukoze u krvi Download PDFInfo
- Publication number
- HRP20140194T1 HRP20140194T1 HRP20140194AT HRP20140194T HRP20140194T1 HR P20140194 T1 HRP20140194 T1 HR P20140194T1 HR P20140194A T HRP20140194A T HR P20140194AT HR P20140194 T HRP20140194 T HR P20140194T HR P20140194 T1 HRP20140194 T1 HR P20140194T1
- Authority
- HR
- Croatia
- Prior art keywords
- ppm
- metformin
- salt according
- salt
- glycine
- Prior art date
Links
- KOFRCHIVYXPUNL-UHFFFAOYSA-N 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical class NCC(O)=O.CN(C)C(=N)N=C(N)N KOFRCHIVYXPUNL-UHFFFAOYSA-N 0.000 title claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 4
- 238000005481 NMR spectroscopy Methods 0.000 claims 4
- 229960003105 metformin Drugs 0.000 claims 3
- 229950007228 metformin glycinate Drugs 0.000 claims 3
- 238000001228 spectrum Methods 0.000 claims 3
- 238000013265 extended release Methods 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 metformin chloride salt Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (8)
1. Metformin glicinat sol.
2. Sol prema zahtjevu 1, naznačena time što protonski spektar nuklearne magnetske rezonance (NMR) pokazuje pomake na 2,814 ppm, 2,916 ppm, i 4,677 ppm.
3. Sol prema zahtjevu 1, naznačena time što C-13 spektar nuklearne magnetske rezonance (NMR) pokazuje pomake na 37,754 ppm, 44,824 ppm, 158,761 ppm, 160,308 ppm, i 180,049 ppm.
4. Sol prema zahtjevu 1, naznačena time što infracrveni (IR) spektar pokazuje karakteristične signale apsorpcije na 3,367.34 cm-1, 3,175.88 cm-1, 1,618.78 cm-1, i 1,573.96 cm-1.
5. Sol prema zahtjevu 1, kao djelatna tvar u farmaceutskoj smjesi u obliku tablete, kaplete, gela, paste, praška, granula s produljenim oslobađanjem, kapsule, tablete s produljenim oslobađanjem, tekućine s puferom, šumeće tablete, suspenzije, sirupa ili aerosola.
6. Postupak proizvodnje soli metformin glicinat, obuhvaća sljedeće korake:
- otopina soli metforminklorida prolazi kroz ionsko-izmjenjivačku kolonu radi dobivanja slobodnog metformina,
- taj slobodni metformin se otapa u vodenom mediju i zatim se dodaje glicin na sobnoj temperaturi uz stalno miješanje,
- dobiveni produkt se zagrijava do ukoncentriravanja te se dodaje organsko otapalo u kojem je glicin netopljiv sve dok se višak glicina ne istaloži,
- istaloženi glicin se filtrira i dobiveni filtrat se koncentrira da se dobije talog metformin glicinata,
- taj talog metformin glicinata se ispire i pročišćava.
7. Sol prema zahtjevu 1 za uporabu u liječenju hiperglikemije u toplokrvnih životinja, to liječenje se sastoji u primjeni različitih doza metformin glicinata različitim putovima, točnije: intravenskom injekcijom, intramuskularnom injekcijom, nazalno, intraperitonealno ili sublingvalno.
8. Sol prema zahtjevu 7, gdje se radi o oralnoj primjeni.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/002665 WO2009144527A1 (en) | 2008-06-26 | 2008-06-26 | A new metformin glycinate salt for blood glucose control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140194T1 true HRP20140194T1 (hr) | 2014-06-20 |
Family
ID=40383805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140194AT HRP20140194T1 (hr) | 2008-06-26 | 2014-03-03 | Nova sol metformin glicinat za kontrolu glukoze u krvi |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8703183B2 (hr) |
| EP (1) | EP2303838B1 (hr) |
| JP (1) | JP5551691B2 (hr) |
| KR (1) | KR101522066B1 (hr) |
| CN (1) | CN102159539B (hr) |
| AR (1) | AR074159A1 (hr) |
| AU (1) | AU2008357111B2 (hr) |
| BR (1) | BRPI0822909B8 (hr) |
| CA (1) | CA2729035C (hr) |
| CL (1) | CL2009001484A1 (hr) |
| CY (1) | CY1115098T1 (hr) |
| DK (1) | DK2303838T3 (hr) |
| EC (1) | ECSP10010719A (hr) |
| ES (1) | ES2450148T3 (hr) |
| HR (1) | HRP20140194T1 (hr) |
| JO (1) | JO2884B1 (hr) |
| MA (1) | MA32418B1 (hr) |
| MX (1) | MX2011000135A (hr) |
| NI (1) | NI201000234A (hr) |
| PE (1) | PE20100257A1 (hr) |
| PL (1) | PL2303838T3 (hr) |
| PT (1) | PT2303838E (hr) |
| SI (1) | SI2303838T1 (hr) |
| TN (2) | TN2010000604A1 (hr) |
| UY (1) | UY31945A (hr) |
| WO (1) | WO2009144527A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009144527A1 (en) | 2008-06-26 | 2009-12-03 | Laboratorios Silanes, S.A. De C.V. | A new metformin glycinate salt for blood glucose control |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| CN103263405B (zh) * | 2013-05-08 | 2015-04-22 | 南京医科大学 | 用于治疗糖尿病的药物组合物及其应用 |
| US9815777B2 (en) | 2013-09-22 | 2017-11-14 | Jiva Pharma, Inc. | Metformin salts to treat Type2 diabetes |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| EP3140316A1 (en) | 2014-05-05 | 2017-03-15 | Thetis Pharmaceuticals LLC | Compositions and methods relating to ionic salts of peptides |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| WO2015195491A1 (en) | 2014-06-18 | 2015-12-23 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of active agents |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| US9892234B2 (en) | 2014-10-27 | 2018-02-13 | Aseko, Inc. | Subcutaneous outpatient management |
| CN105030745A (zh) * | 2015-07-08 | 2015-11-11 | 南京医科大学 | 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用 |
| EP3337402A4 (en) | 2015-08-20 | 2019-04-24 | Aseko, Inc. | THERAPY ADVISER FOR THE MANAGEMENT OF DIABETES |
| EP3454907B1 (en) | 2016-06-03 | 2020-07-22 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
| US11510886B2 (en) | 2016-09-30 | 2022-11-29 | Laboratorios Silanes, S.A. De C.V. | Metformin amino acid compounds and methods of using the same |
| MX2019003725A (es) | 2016-09-30 | 2019-08-12 | Laboratorios Silanes S A De C V | Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma. |
| CN113105367B (zh) * | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE568513A (hr) | ||||
| FR2037002A1 (en) | 1969-04-30 | 1970-12-31 | Roques Bernard | N-substd biguanide pamoic acid salts prepn |
| DE1967138A1 (de) | 1969-07-17 | 1977-11-10 | Christian Brunnengraeber Chem | Therapeutisches mittel |
| AT325632B (de) | 1973-06-01 | 1975-10-27 | Hurka Wilhelm | Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids |
| FR2243684B1 (hr) | 1973-09-19 | 1977-01-28 | Semb | |
| CH602612A5 (hr) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| FR2320735A1 (fr) | 1975-08-12 | 1977-03-11 | Dabis Georges | Composition anti-cellulite |
| JPS57179494A (en) | 1981-04-30 | 1982-11-05 | Mitsubishi Plastics Ind | Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction |
| FR2585572B3 (fr) | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
| PT793646E (pt) * | 1994-11-23 | 2002-03-28 | Biovitrum Ab | Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente |
| ES2216335T3 (es) | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| WO2003068209A1 (en) * | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| US7181457B2 (en) * | 2003-05-28 | 2007-02-20 | Pervasive Software, Inc. | System and method for utilizing compression in database caches to facilitate access to database information |
| EP1677758A1 (en) | 2003-10-31 | 2006-07-12 | ALZA Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| WO2005065675A1 (en) | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
| WO2006086856A1 (en) * | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
| CN101180073A (zh) * | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
| US7973073B2 (en) * | 2006-06-16 | 2011-07-05 | Indigene Pharmaceuticals, Inc. | Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
| NZ556735A (en) * | 2007-07-24 | 2009-03-31 | Vector Ltd | Securing devices and equipotential bonding system |
| WO2009144527A1 (en) | 2008-06-26 | 2009-12-03 | Laboratorios Silanes, S.A. De C.V. | A new metformin glycinate salt for blood glucose control |
-
2008
- 2008-06-26 WO PCT/IB2008/002665 patent/WO2009144527A1/en active Application Filing
- 2008-06-26 DK DK08807218.6T patent/DK2303838T3/en active
- 2008-06-26 PT PT88072186T patent/PT2303838E/pt unknown
- 2008-06-26 MX MX2011000135A patent/MX2011000135A/es active IP Right Grant
- 2008-06-26 JP JP2011515639A patent/JP5551691B2/ja not_active Expired - Fee Related
- 2008-06-26 BR BRPI0822909A patent/BRPI0822909B8/pt active IP Right Grant
- 2008-06-26 PL PL08807218T patent/PL2303838T3/pl unknown
- 2008-06-26 KR KR1020117000071A patent/KR101522066B1/ko active IP Right Grant
- 2008-06-26 CN CN200880130084.3A patent/CN102159539B/zh active Active
- 2008-06-26 EP EP08807218.6A patent/EP2303838B1/en not_active Not-in-force
- 2008-06-26 ES ES08807218.6T patent/ES2450148T3/es active Active
- 2008-06-26 AU AU2008357111A patent/AU2008357111B2/en not_active Ceased
- 2008-06-26 SI SI200831163T patent/SI2303838T1/sl unknown
- 2008-06-26 CA CA2729035A patent/CA2729035C/en not_active Expired - Fee Related
-
2009
- 2009-06-25 PE PE2009000908A patent/PE20100257A1/es active IP Right Grant
- 2009-06-25 JO JO2009233A patent/JO2884B1/en active
- 2009-06-25 CL CL2009001484A patent/CL2009001484A1/es unknown
- 2009-06-26 AR ARP090102388A patent/AR074159A1/es unknown
- 2009-06-26 UY UY0001031945A patent/UY31945A/es not_active Application Discontinuation
-
2010
- 2010-12-23 NI NI201000234A patent/NI201000234A/es unknown
- 2010-12-24 US US12/928,985 patent/US8703183B2/en not_active Ceased
- 2010-12-24 EC EC2010010719A patent/ECSP10010719A/es unknown
- 2010-12-27 MA MA33460A patent/MA32418B1/fr unknown
- 2010-12-27 TN TNP2010000604A patent/TN2010000604A1/fr unknown
- 2010-12-27 TN TNP2010000607A patent/TN2010000607A1/fr unknown
-
2014
- 2014-02-25 CY CY20141100150T patent/CY1115098T1/el unknown
- 2014-03-03 HR HRP20140194AT patent/HRP20140194T1/hr unknown
-
2016
- 2016-04-21 US US15/135,018 patent/USRE46496E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140194T1 (hr) | Nova sol metformin glicinat za kontrolu glukoze u krvi | |
| CN101987094B (zh) | 门冬氨酸鸟氨酸注射液及其制备方法 | |
| CN106349245A (zh) | 一种磷酸西格列汀杂质及其制备方法和用途 | |
| CN105017175B (zh) | 一种沃替西汀的制备方法 | |
| ITRM20130135A1 (it) | Nuovi derivati del resveratrolo. | |
| RU2396077C1 (ru) | ВОДОРАСТВОРИМОЕ КОМПЛЕКСНОЕ СОЕДИНЕНИЕ ВКЛЮЧЕНИЯ ДИГИДРОКВЕРЦЕТИНО-β-ЦИКЛОДЕКСТРИН И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| US20140171659A1 (en) | Method for purifying (s)-oxiracetam | |
| CN105348262B (zh) | 一种制备达比加群酯的改进方法 | |
| CN102846600A (zh) | 一种奥拉西坦药物活性组合物及其制备方法 | |
| CN103664805B (zh) | 一种制备阿昔莫司的方法 | |
| CN104672210A (zh) | 阿格列汀和苯甲酸阿格列汀的制备方法 | |
| JP4566128B2 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
| CN104004040B (zh) | 一种利用草酰氯制备胞磷胆碱钠的方法 | |
| CN103145636A (zh) | 一种1,4-二酰基-3,6-二苯基-1,4-二氢均四嗪类化合物及其制备方法和应用 | |
| US11098007B2 (en) | Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof | |
| CN102030693B (zh) | 乙酰半胱氨酸化合物及其新方法 | |
| CN101955511A (zh) | 氧化型谷胱甘肽及其碱金属盐的合成方法 | |
| CN104230745B (zh) | 一类n-苄基取代的氨基水杨酸与4-氨基丁酸的酰胺衍生物及其药物用途 | |
| ES2899261T3 (es) | Cristales de una sal de un catión monovalente de ácido 3-hidroxiisovalérico y método para producir dichos cristales | |
| CN102731430B (zh) | 非布司他的晶型和其制备方法以及应用 | |
| CN100509787C (zh) | 吡硫醇的新的药学上可接受的盐及其制备方法 | |
| CN102977039B (zh) | 6-氟-3-羟基-2-吡嗪甲酰胺α晶型及其制备方法 | |
| CN111548313A (zh) | 预防和治疗慢性疼痛药物的胍类化合物 | |
| CN109810094A (zh) | 一种阿格列汀的制备方法 | |
| EP3345898A1 (en) | Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1h-indol-5-yl)amino)nicotinic acid |